Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

BACKGROUND: An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust efficacy in ulcerative colitis patients although, like other systemic immunosuppre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Inflamm (Lond)
Main Authors: Beattie, David T., Pulido-Rios, M. Teresa, Shen, Fei, Ho, Melissa, Situ, Eva, Tsuruda, Pam R., Brassil, Patrick, Kleinschek, Melanie, Hegde, Sharath
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718031/
https://ncbi.nlm.nih.gov/pubmed/29225517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12950-017-0175-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares